Roth MKM Maintains Buy on Helius Medical Tech, Adjusts Price Target To $24
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has maintained a Buy rating on Helius Medical Technologies (NASDAQ:HSDT) and adjusted the price target to $24 from $5.
March 05, 2024 | 6:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM analyst Jonathan Aschoff has reaffirmed a Buy rating on Helius Medical Technologies and increased the price target significantly to $24 from $5.
The substantial increase in the price target from $5 to $24 by a reputable analyst suggests a strong bullish outlook on Helius Medical Technologies. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100